课题基金 / 基金详情

Newton Fund - Development of a rapid ParaDNA test kit for improved clinical management of patients with breast cancer and associated co-morbidities

Newton Fund - Development of a rapid ParaDNA test kit for improved clinical management of patients with breast cancer and associated co-morbidities
牛顿基金 - 开发一种快速 ParaDNA 检测试剂盒,以改善乳腺癌及相关并发症患者的临床管理
批准号:
103993
负责人:
金额:
$23.82万
依托单位:
依托单位国家:
英国
项目类别:
Collaborative R&D
财政年份:
2018
资助国家:
英国
项目状态:
已结题
起止时间:
2018 至 --

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
包括癌症和心血管疾病在内的非传染性疾病是全球死亡的主要原因。南非医学研究理事会(SAMRC)通过支持开发一个新的基因检测平台来应对可翻译研究的迫切需求,该平台侧重于许多非传染性疾病共有的疾病途径。为了与联合国确保健康和促进福祉的可持续发展目标相联系,LGC(英国)与SAMRC的衍生公司Gknowmix和Stellenbosch大学合作开发了一种新型的床旁(Point of Care)诊断测试系统和筛查工具,以改善乳腺癌及其相关并发症患者的临床管理。该检测平台通过使用LGC ParaDNA技术实现,该技术能够检测在乳腺癌发展中重要的遗传变化。基因检测可以由非专家用户在1小时内完成,而标准实验室方法从样本收集到结果报告需要1周。这项技术将首次用于检测两种主要乳腺癌易感基因(BRCA 1和BRCA 2)的变化,以及各种非传染性疾病共有的其他基因的变化。使用该技术生成的患者报告有助于确定是否有必要对治疗失败、药物副作用或初始评估无法解释的合并症患者进行进一步测试。将独特的ParaDNA测序技术与Gknowmix的专有算法相结合,使该系统能够在南非和全球范围内扩展,对乳腺癌患者以及有患心血管疾病和其他相关非传染性疾病风险的患者有显著的益处。在卫生局进行基因检测,可以更好地获得基因检测和全面护理,降低成本,更快地报告,以便及时实施有效的干预战略。
英文摘要
Non-communicable diseases (NCDs) including cancer and cardiovascular disease (CVD) are major causes of death globally. The South African Medical Research Council (SAMRC) has responded to the dire need for translatable research by supporting the development of a novel genetic testing platform focused on disease pathways that are shared by many NCDs. To link to the United Nations' Sustainable Development Goal of ensuring health and promoting well-being, LGC (UK) in collaboration with the SAMRC's spinout company, Gknowmix, and Stellenbosch University has developed a novel point of care (PoC) diagnostic testing system and screening tool to improve the clinical management of patients with breast cancer and its associated co-morbidities. This testing platform is made possible by using the LGC ParaDNA technology that enables detection of genetic changes that are important in the development of breast cancer. Genetic testing may be done by non-expert users and within 1 hour, compared to standard laboratory methods that takes 1 week from sample collection to result reporting. For the first time, PoC technology will be used to detect changes in the two main breast cancer susceptibility genes (BRCA1 and BRCA2), as well as changes in other genes shared by various NCDs. The patient reports generated using this technology helps to determine whether further testing is necessary in patients with treatment failure, medication side-effects or co-morbidities that are not explained by the initial assessment. Combining the unique ParaDNA PoC technology with the proprietary algorithms of Gknowmix, enables this system to be scaled in South Africa and globally, with significant benefit to patients with breast cancer and those at risk of developing CVD and other associated NCDs. The availability of genetic testing at the PoC enables better access to genetic testing and overall care, reduced costs and faster reporting for timely implementation of effective intervention strategies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金